Anavex Life Sciences Corp (AVXL)

[boi568]

Blarcamesine probably didn't help the fewer than 10 percent of unfortunate patients with mutations in both S1R and COL24A1. It probably just lessened or eliminated the relative underperformance of patients with either an S1R or COL24A1 mutation (which makes it worthwhile but would not have much commercial impact).